You are here
Medibio Receives TGA Approval
SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform.
The Company’s regulatory validation now includes both the CE (Conformité Européenne) Mark and Therapeutic Good Administration (TGA) under the GMDN product code 58290 - Psychological assessment system application software.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
|Further Information: Website: www.medibio.com.au|
|Shareholder and Investor Inquiries:|
Investor Relations Director
T: +61 434 405 400
Senior Public Relations Manager
T: +1 952-222-0551 ext. 208
M: +1 612-695-0168